Amneal Q1 2026 revenue rises 4% to $723 million; net income reaches $62 million
Amneal Pharmaceuticals reported first-quarter 2026 net revenue of $723 million, up 4% from $695 million a year earlier, and GAAP net income attributable to the company of $62 million, up from $12 million. The company affirmed the full-year 2026 guidance it raised on April 22, 2026, which calls for net revenue of $3.05 billion to $3.15 billion and adjusted diluted EPS of $0.95 to $1.05.
Key points
- Q1 2026 diluted EPS was $0.19 versus $0.04 in Q1 2025; adjusted diluted EPS was $0.27, up 29%.
- Adjusted EBITDA was $202 million, up 19% from $170 million in Q1 2025.
- Specialty net revenue rose 23%, while AvKARE net revenue fell 4%.
- Net cash used in operating activities was $26.7 million in Q1 2026, compared with $7.4 million provided in Q1 2025.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.